SCHEDULE: Glazer Capital Reports 0% Stake in Ventyx Biosciences

Glazer Capital, LLC and Paul J. Glazer have filed a Schedule 13G, reporting no beneficial ownership of Ventyx Biosciences, Inc. common stock as of March 31, 2026.

Summary

• Glazer Capital, LLC and Paul J. Glazer have filed an amendment to their Schedule 13G filing concerning Ventyx Biosciences, Inc.
• As of March 31, 2026, the reporting persons, Glazer Capital, LLC and Paul J. Glazer, reported that they beneficially own 0 shares of Ventyx Biosciences, Inc. common stock.
• This represents 0.00% of the class of securities.
• Glazer Capital, LLC serves as the investment manager for certain funds and managed accounts that hold the securities, while Paul J. Glazer is the Managing Member of Glazer Capital, LLC.
• The filing explicitly states that the filing should not be construed as an admission that any reporting person is the beneficial owner of the securities reported.

Sentiment

Score: 2

Explanation: StockSavvy.ai views this filing as having a very low sentiment score due to the reporting of zero beneficial ownership, indicating no current investment or interest from a significant institutional holder.

Negatives

• Glazer Capital, LLC and Paul J. Glazer reported zero beneficial ownership of Ventyx Biosciences, Inc. common stock, indicating no investment position as of the reporting date.

Future Outlook

No forward-looking statements or guidance were provided in this filing.

Management Comments

• The filing of this statement should not be construed as an admission that any of the Reporting Persons is, for the purposes of Section 13 of the Act, the beneficial owner of the shares of Common Stock reported herein.

Industry Context

StockSavvy.ai notes that Schedule 13G filings are typically made by institutional investors who acquire beneficial ownership of more than 5% of a class of a company's registered equity securities. A filing reporting 0% ownership, especially as an amendment, can indicate a complete divestment or a correction of a previous filing, suggesting a lack of current significant interest from Glazer Capital in Ventyx Biosciences.

Stakeholder Impact

• Shareholders may note the absence of Glazer Capital as a significant institutional holder, which could influence perceptions of institutional support for Ventyx Biosciences.

Key Dates

Keywords

Ventyx Biosciences, Schedule 13G, Glazer Capital, Paul J. Glazer, SEC Filing, Beneficial Ownership, Common Stock